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Abstract
Background: ESBL (Extended spectrum beta-lactamase) producing enterobacteriaceae are challenging organisms
with little treatment options. Carbapenems are frequently used, but the emergence of carbapenem resistant
enterobacteriaceae is a concerning issue, which may hinder the use of carbapenems. Although cephamycins
such as cefoxitin, cefmetazole or cefotetan are effective against ESBL-producers in vitro, there are few clinical
data demonstrating effects against bacteremia caused by these organisms.
Methods: We performed a retrospective observational study on cases of bacteremia caused by ESBL-producers to
investigate the efficacy of cefmetazole compared with carbapenems. We also evaluated whether the trend of antibiotic
choice changed over years.
Results: Sixty-nine patients (male 34, age 69.2 ± 14.4), including two relapse cases, were reviewed for this analysis.
The most common causative organisms were Escherichia coli (64, 93 %), followed by Klebsiella pneumoniae and K.
oxytoca (2 each, 4 %). The group that received carbapenem therapy (43, 62 %) had increased severity in the
Pittsburgh Bacteremic score than the group that received cefmetazole therapy, (1.5 ± 1.5 vs 2.5 ± 2.1, p = 0.048),
while analysis of other factors didn’t reveal any statistical differences. Five patients in the carbapenem group and
one patient in the cefmetazole group died during the observation period (p = 0.24). CTX-M-9 were predominant
in this series (59 %). Infectious disease physicians initially recommended carbapenems at the beginning of the
current research period, which gradually changed over time favoring the use of cefmetazole instead (p = 0.002).
Conclusion: Cefmetazole may be safely given to patients with bacteremia caused by ESBL-producers as a definitive
therapy, if one can select out relatively stable patients.
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Background
Spreading antibiotic resistance is a global concern. In
terms of enterobacteriaceae, extended spectrum beta
lactamase (ESBL) producing enterobacteriaceae and
carbapenem resistant enterobacteriaceae (CRE) are the
most concerning pathogens [1]. Infections caused by
ESBL producing enterobacteriaceae (ESBL-E) are asso-
ciated with higher mortality [2] and medical cost [3–5].
There is a strong relationship between antibiotic use
and increase in prevalence of resistant pathogens. The
drugs most often used against ESBL-producers are car-
bapenems [6]. Research has elucidated that recent ex-
posure (3 months prior) to antibiotics was a parameter
consistently associated with detection of CRE [7, 8].
Overuse of carbapenems and subsequent selective
pressure can contribute to the spread of CRE. CREs
are rarely identified in Japan as of this writing, but
overreliance on carbapenems may induce CREs. Thus,
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CRE became an emerging pathogen, especially in Europe
and North America.
Cephamycins, such as cefmetazole and flomoxef have
good activity against ESBL-producers in vitro. However,
clinical data regarding the potential value of cephamy-
cins for the treatment of ESBL-associated infections are
scarce [9]. Some are also reluctant to use cephamycins
as first-line therapy for ESBL-producing organisms [10].
We therefore conducted a study to evaluate the effi-
cacy of cefmetazole against bacteremia caused by ESBL-
E. In addition, the trend of the prescription of antibiotics
against ESBL-E bacteremia were evaluated over years to
see the effectiveness of Infectious Disease consultants in
avoiding the overuse of carbapenems.
Methods
We conducted a retrospective observational study at a
930-bed university hospital in Kobe, Japan. All patients
admitted from 1st January 2008 through until 31 De-
cember 2013 who had ESBL-E isolated from blood cul-
tures were identified. The clinical records of all 125 who
had positive blood cultures of ESBL-E, and those who
were treated with carbapenems or cefmetazole as defini-
tive therapy were reviewed. ESBL-E were defined as
positive strains of the double disc synergy test [11].
Duplicated cultures, pediatric patients, those judged as
contamination by the infectious disease team, and pallia-
tive care patients were excluded.
The following data was collected from the clinical re-
cords; age, gender, community acquired or nosocomial
infection, origin of bacteremia, causative pathogens, co-
morbidities (using Charlson comorbidity scoring index;
myocardial infarction, congestive heart failure, peripheral
vascular disease, dementia, chronic pulmonary disease,
connective tissue disease, peptic ulcer disease, liver dis-
ease, diabetes mellitus, hemiplesia, renal disease, tumor
or lymphoma with or without metastasis, leukemia, and
AIDS), vital signs (using Pittsburgh bacteremic Score
and SOFA score), admission into ICU, bacterial profile
(single pathogen or mixed infections, resistance against
cefmetazole, resistance against fluoroquinolones), treat-
ment profile (empirical treatment, definitive treatment,
consultation with infectious disease physicians, the effi-
cacy of empirical antibiotics).
Primary outcomes were defined as a death within
30 days after the documentation of bacteremia and a re-
lapse of bacteremia caused by the same pathogen.
In addition, we evaluated the relationship between
treatment options and consultation with infectious dis-
ease physicians over years. Furthermore, we estimated
the resistant genes of ESBL-E. Genetic detection and
genotyping of TEM, SHV, and CTX-M were performed
by using PCR with bacterial DNA, which was extracted
from the isolates by boiling the bacterial suspensions. A
solution with an extracted DNA concentration of 0.1 ng/
mL was used as the template for PCR analysis. In the
case of genotyping of CTX-M genes, 4 primer sets that
amplify group-specific CTX-M genes were used, as de-
scribed previously: the CTX-M1 group includes CTX-
M-1, CTX-M-3, CTX-M-10 to CTX-M-12, CTX-M-15,
CTX-M-22, CTX-M-23, and CTX-M-28 to CTX-M-30;
the CTX-M2 group, CTX-M-2, CTX-M-4 to CTX-M-7,
CTX-M-20, and Toho-1; the CTX-M8 group, CTX-M-8;
and the CTX-M9 group, CTX-M-9, CTX-M-13, CTX-
M-14, CTX-M-16 to CTX-M-19, CTX-M-21, CTX-M-
27, and Toho-2. The PCR products were analyzed using
2 % agarose gel electrophoresis and visualized by stain-
ing with ethidium bromide.
The statistical analysis was performed using STATA 13
(STATA corp. LP, College Station, Texas, USA). The
Mann-Whitney test was used to compare the two
groups, also an extension to the Wilcoxon rank-sum
test, the ‘nptrend’ STATA command, was used to assess
trends in proportions across ordered groups. All test
were two-tailed and p values ≤ 0.05 were used for statis-
tical significance testing.
Result
Sixty-nine patients with ESBL-E bacteremia were
reviewed for the analysis (Fig. 1). Twenty-six (38 %) pa-
tients were given cefmetazole (CMZ) as definitive ther-
apy, while 43 patients (62 %) were given carbapenems
(CPs), of which meropenem was used most (39),
followed by doripenem (3), and biapenem (1). The
average age of the patients was 67.5 ± 14.6 and 71.2 ±
13.0 in CMZ group and CPs group, respectively
(Table 1, P = 0.18). SOFA score tended to be higher in
CPs group, although it did not reach statistical signifi-
cance (P = 0.055). The Pittsburgh Bacteremic Score in
the CPs group was significantly higher than CMZ
group (P = 0.048). The most frequent origin of infection
was the urinary tract in both groups (CMZ group: 18,
69 %, CPs group: 17, 40 %), followed by hepatobiliary
infections (CMZ group: 5, 20 %, CPs group: 8, 19 %).
The most frequently isolated pathogens were Escheri-
chia coli in both groups (CMZ group: 25, 96 %, CPs
group: 39, 91 %). The CMZ group had one case caused
by Klebsiella pneumoniae, and the CPs group had two
K. oxytoca and one K. penumoniae. The most used em-
piric therapies in the CPs group were carbapenems (27;
meropenem 21, doripenem 3, biapenem 2, imipenem/
cilastatin 1), followed by cefazolin (5), ceftriaxone (4),
sulbactam/cefoperazone (3) (Table 2). The most used
empiric therapies in the CMZ group were meropenem
(6) followed by cefepime (4), tazobactam/piperacillin
(4), sulbactam/ampicillin (3), ceftriaxone (3), cefmeta-
zole (2). Antibiotic coverage rates are shown in Table 1.
Genetic analysis revealed CTX-M-9 was predominant
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in isolated strains in this series (39, 59 %), followed by
CTX-M-1 (21, 32 %), M2, TEM/SHV, KOXY (2 each,
3 %).
Six patients died during the study period (CMZ group:
1, CPs group: 5), while 2 patients in the CPs group re-
lapsed (became bacteraemic) after treatment with mero-
penem. As a result, 96 % of patients in the CMZ group
and 84 % of patients in the CPs group survived without
relapse (p = 0.24).
The CPs group and the CMZ group had resistant
genes such as CTX-M9 (20, 16), CTX-M1 (13, 7), CTX-
M2 (1, 1), KOXY (2, 0), TEM/SHV (2, 0), respectively.
Five patients in the CPs group died, and their ESBLs
were CTX-M9 (1), CTX-M1 (3), KOXY (1).
Resistance against cefmetazole was rare (only 1 case in
CPs group, or 1 %).
The consultation to infectious disease physicians tended
to be higher in the CMZ group, (75 % vs 49 %, p = 0.077).
The selection of antibiotics, ID consultation, and out-
comes of each-year are shown in Fig. 2. The CMZ group
and the CPs group had a significant difference in trend
over years with the use of CMZ becoming much more
popular recently (p = 0.02).
Discussion
This observational study demonstrated that bacteremia
caused by ESBL-E were effectively treated with cefmeta-
zole as definitive therapy, and this suggests cefmetazole
can be a candidate as an alternative for carbapenems.
The patients in both groups had low mortality. Of note,
relapse of bacteremia caused by ESBL-producer oc-
curred only in the carbapenems group, although these
relapsed patients were originally treated with sufficient
quantity and duration of carbapenems.
Over years both cases with and without Infectious Dis-
eases physician consults started to use CMZ as the de-
finitive therapy probably due to confidence in the use of
CMZ against ESBL-E (Fig. 2).
The rationale of antimicrobial therapy against sepsis
or bacteremia is as follows. As empirical therapy, broad-
spectrum antibiotics must be selected with one or more
agents active against likely bacterial pathogens after
obtaining appropriate cultures. It should be reevaluated
according to the results of cultures to optimize efficacy,
to prevent resistance, to avoid toxicity, and to minimize
costs [12]. When treating ESBL-producers, carbapenems
have unnecessary coverage against non-fermenters such
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Fig. 1 Enrollment of the patients
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male 12 22 -
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SOFA 2.8 + -2.8 5.0 + -4.5 0.055
Charlson 7.1 + -3.4 6.8 + -2.8 0.85
Pitt. Bact. Score 1.5 + -1.5 2.5 + -2.1 0.048
admission to ICU 5 (24 %) 17 (39 %) 0.111
community
acquired
10 (38 %) 11(26 %) 0.29
Bacterial
profile
mixed infection 2 (8 %) 7 (16 %) 0.466
cefmetazole:R 0 (0 %) 1 (2 %) 1
fluoroquinolone:R 19 (73 %) 34 (79 %) 1
Treatment
profile
ID consult 19 (73 %) 21 (49 %) 0.077
empiric cover 13 (50 %) 27 (63 %) 0.325
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Cefmetazole has a narrower spectrum compared to car-
bapenems and does not cover Pseudomonas or Acinetobac-
ter. These characteristics would provide another advantage
of cefmetazole over carbapenems. Cefmetazole can play an
important role in antimicrobial stewardship programs.
Studies have shown the efficacy of cefmetazole against
ESBL producing enterobacteriaceae. Matsumura et al.
found that treatment with cefmetazole or flomoxef
against bacteremia caused by ESBL-producing E. coli
were similarly effective compared with treatment with
carbapenems in a retrospective multicenter study using
a propensity score-adjusted analysis [13]. This study
demonstrated the efficacy of two cephamycins against
ESBL-producing E.coli in both empirical and definitive
therapy cohorts. However, use of cefmetazole as an em-
pirical therapeutic agent is not realistic, because one
cannot predict whether the causative pathogens were
really ESBL-E prior to the culture result. Therefore, we
rather tried to focus on definitive therapy alone, where
cefmetazole could be utilized better.
Doi A et al. showed the efficacy of cefmetazole against
pyelonephritis caused by ESBL-producing enterobacteri-
aceae [14]. Bacteremic patients were not included in the
CMZ group in this study (0/7), as opposed to carbapen-
ems (8/12). Our study focused on bacteremic patients,
which makes our results applicable in a wider setting.
Considering other candidates, there are various studies
claiming the efficacy of beta-lactam/beta-lactamase
inhibitor (BLBLI) against ESBL-producers, but with
some controversies. Piperacillin/tazobactam is a prom-
ising antibiotic, although piperacillin has unnecessary
coverage against Pseudomonas. In addition, the role of
piperacillin/tazobactam for patients with ESBL-E
remains unclear. A meta-analysis described BLBLI as
being non inferior compared to carbapenems [2].
However, some research in the US and Taiwan and a
cohort study in the US showed higher mortality when
piperacillin/tazobactam is used when compared with
carbapenems [6, 15, 16].
On the other hand, ertapenem has good activity
against ESBL producers, and has the advantage of not
covering Pseudomonas, a different characteristic from
other carbapenems [17]. Ertapenem is still much broader
than CMZ, making CMZ more advantageous over erta-
penem. Ertapenem use led to the selection of multi-drug
resistant bacteria at a Singapore hospital [18].
By the same token, cefepime could be effective
against the strains in North America. In East Asia,
however, it has less activity against ESBL-E (78.6 %)
[19]. Similarly, aminoglycosides keep their activity
against ESBL-E. Despite this, many physicians are re-
luctant to use aminoglycosides for fear of adverse ef-
fects such as nephrotoxicity [20].
Regarding the diversity of ESBL-E, there are at least
300 strains in the world. Taiwanese research revealed
high resistance of ESBL-E against CMZ (40 %), but most
were CTX-M-14 or CTX-M-15 [21]. In our study, CTX-
M-9 was the most common strain (51 %).
There are several limitations in this study. First, this
is only a retrospective observational study at one insti-
tution. Resistance patterns differ among hospitals, re-
gions, or countries. Our results might not be applied to
other settings, particularly where the genotype of ESBL
producers are different. However, settings with similar
resistant patterns to our hospital may use CMZ like our
practice. Secondly, our patients had relatively less se-
vere infection than those in the previous studies. Third,
selection bias could not be completely removed in both
groups.
Even though we are aware of these limitations, the fact
that most patients with bacteremia caused by ESBL-
producers were successfully treated with cefmetazole
was quite promising. For clinically stable patients, who
are already improving on empirical antimicrobial treat-
ment, or without clinical deterioration can be a good
candidate for de-escalation to cefmetazole with close
clinical monitoring. Prospective studies in various set-
tings may confirm our findings in the future.
Table 2 Empiric therapies and proportion of unfavorable outcomes on both groups of cefmetazole (CMZ) and carbapenems (CPs)
CMZ group CPs group
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Conclusion
Our study suggests cefmetazole may be effective against
bacteremia due to ESBL-producing Enterobacteriaceae
as a definitive therapy, therefore allowing the sparing of
carbapenems against the organisms. Further research,
such as prospective interventional studies are needed to
confirm our findings.
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